Abstract
Background:
Over the last years, several trials offered new evidence on heart failure (HF) treatment.
Design and results:
For HF with reduced left ventricular ejection fraction, type 2 sodium-glucose cotransporter inhibitors, aside from sacubitril-valsartan, demonstrated extraordinary efficacy in ameliorating patients' prognosis. Some new molecules (eg vericiguat, omecamtiv mecarbil and ferric carboxymaltose) correct iron deficiency and have shown to be capable of furthering reducing the burden of HF hospitalisation. Finally, there is new evidence on the possible therapeutic approaches of HF patients with mid-range or preserved left ventricular ejection fraction.
Conclusions:
This review aimed to revise the main novelties in the field of HF therapy and focus on how the daily clinical approach to patient treatment is changing.
Keywords:
heart failure; prognosis; therapy.
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
MeSH terms
-
Aminobutyrates / therapeutic use
-
Angiotensin Receptor Antagonists / therapeutic use*
-
Biphenyl Compounds / therapeutic use
-
Cardiotonic Agents / therapeutic use*
-
Drug Combinations
-
Ferric Compounds / therapeutic use
-
Heart Failure / complications
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Heterocyclic Compounds, 2-Ring / therapeutic use
-
Hospitalization / statistics & numerical data*
-
Humans
-
Iron Deficiencies / complications
-
Iron Deficiencies / drug therapy
-
Maltose / analogs & derivatives
-
Maltose / therapeutic use
-
Pyrimidines / therapeutic use
-
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
-
Stroke Volume / physiology
-
Urea / analogs & derivatives
-
Urea / therapeutic use
-
Valsartan / therapeutic use
-
Vasodilator Agents / therapeutic use*
-
Ventricular Remodeling
Substances
-
Aminobutyrates
-
Angiotensin Receptor Antagonists
-
Biphenyl Compounds
-
Cardiotonic Agents
-
Drug Combinations
-
Ferric Compounds
-
Heterocyclic Compounds, 2-Ring
-
Pyrimidines
-
Sodium-Glucose Transporter 2 Inhibitors
-
Vasodilator Agents
-
omecamtiv mecarbil
-
ferric carboxymaltose
-
Maltose
-
Valsartan
-
Urea
-
vericiguat
-
sacubitril and valsartan sodium hydrate drug combination